These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 26852222)

  • 1. Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases.
    Wolf A; Zia S; Verma R; Pavlick A; Wilson M; Golfinos JG; Silverman JS; Kondziolka D
    J Neurooncol; 2016 May; 127(3):607-15. PubMed ID: 26852222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment.
    Ly D; Bagshaw HP; Anker CJ; Tward JD; Grossmann KF; Jensen RL; Shrieve DC
    J Neurosurg; 2015 Aug; 123(2):395-401. PubMed ID: 25768829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases.
    Xu Z; Lee CC; Ramesh A; Mueller AC; Schlesinger D; Cohen-Inbar O; Shih HH; Sheehan JP
    J Neurosurg; 2017 Mar; 126(3):726-734. PubMed ID: 27203149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases.
    Ahmed KA; Freilich JM; Sloot S; Figura N; Gibney GT; Weber JS; Sarangkasiri S; Chinnaiyan P; Forsyth PA; Etame AB; Rao NG
    J Neurooncol; 2015 Mar; 122(1):121-6. PubMed ID: 25519302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases.
    Patel BG; Ahmed KA; Johnstone PA; Yu HH; Etame AB
    Melanoma Res; 2016 Aug; 26(4):382-6. PubMed ID: 26926151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome.
    Kotecha R; Miller JA; Venur VA; Mohammadi AM; Chao ST; Suh JH; Barnett GH; Murphy ES; Funchain P; Yu JS; Vogelbaum MA; Angelov L; Ahluwalia MS
    J Neurosurg; 2018 Jul; 129(1):50-59. PubMed ID: 28799876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies.
    Choong ES; Lo S; Drummond M; Fogarty GB; Menzies AM; Guminski A; Shivalingam B; Clarke K; Long GV; Hong AM
    Eur J Cancer; 2017 Apr; 75():169-178. PubMed ID: 28236768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy.
    Ahmed KA; Abuodeh YA; Echevarria MI; Arrington JA; Stallworth DG; Hogue C; Naghavi AO; Kim S; Kim Y; Patel BG; Sarangkasiri S; Johnstone PA; Sahebjam S; Khushalani NI; Forsyth PA; Harrison LB; Yu M; Etame AB; Caudell JJ
    Ann Oncol; 2016 Dec; 27(12):2288-2294. PubMed ID: 27637745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases.
    Rauschenberg R; Bruns J; Brütting J; Daubner D; Lohaus F; Zimmer L; Forschner A; Zips D; Hassel JC; Berking C; Kaehler KC; Utikal J; Gutzmer R; Terheyden P; Meiss F; Rafei-Shamsabadi D; Kiecker F; Debus D; Dabrowski E; Arnold A; Garzarolli M; Kuske M; Beissert S; Löck S; Linn J; Troost EGC; Meier F
    Eur J Cancer; 2019 Mar; 110():11-20. PubMed ID: 30739835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS).
    Samlowski WE; Watson GA; Wang M; Rao G; Klimo P; Boucher K; Shrieve DC; Jensen RL
    Cancer; 2007 May; 109(9):1855-62. PubMed ID: 17351953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
    Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
    J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.
    Frakes JM; Figura NB; Ahmed KA; Juan TH; Patel N; Latifi K; Sarangkasiri S; Strom TJ; Chinnaiyan P; Rao NG; Etame AB
    J Neurosurg; 2015 Nov; 123(5):1261-7. PubMed ID: 26140482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF V600 Mutation and BRAF Kinase Inhibitors in Conjunction With Stereotactic Radiosurgery for Intracranial Melanoma Metastases: A Multicenter Retrospective Study.
    Mastorakos P; Xu Z; Yu J; Hess J; Qian J; Chatrath A; Taylor DG; Kondziolka D; Warnick R; Chiang V; Sheehan J
    Neurosurgery; 2019 Apr; 84(4):868-880. PubMed ID: 29846702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery.
    Tazi K; Hathaway A; Chiuzan C; Shirai K
    Cancer Med; 2015 Jan; 4(1):1-6. PubMed ID: 25164960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic radiosurgery combined with targeted/ immunotherapy in patients with melanoma brain metastasis.
    Hadi I; Roengvoraphoj O; Bodensohn R; Hofmaier J; Niyazi M; Belka C; Nachbichler SB
    Radiat Oncol; 2020 Feb; 15(1):37. PubMed ID: 32059731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors for survival in patients treated with stereotactic radiosurgery for recurrent brain metastases after prior whole brain radiotherapy.
    Caballero JA; Sneed PK; Lamborn KR; Ma L; Denduluri S; Nakamura JL; Barani IJ; McDermott MW
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):303-9. PubMed ID: 22079723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic Radiosurgery for Melanoma Brain Metastases: A Comprehensive Clinical Case Series.
    Feng R; Oermann EK; Shrivastava R; Gold A; Collins BT; Kondziolka D; Collins SP
    World Neurosurg; 2017 Apr; 100():297-304. PubMed ID: 28093345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent Radiosurgery and Immune Checkpoint Inhibition: Improving Regional Intracranial Control for Patients With Metastatic Melanoma.
    Murphy B; Walker J; Bassale S; Monaco D; Jaboin J; Ciporen J; Taylor M; Dai Kubicky C
    Am J Clin Oncol; 2019 Mar; 42(3):253-257. PubMed ID: 30557166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastatic melanoma: prognostic factors and survival in patients with brain metastases.
    Frinton E; Tong D; Tan J; Read G; Kumar V; Kennedy S; Lim C; Board RE
    J Neurooncol; 2017 Dec; 135(3):507-512. PubMed ID: 28819707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic radiosurgery using the Leksell Gamma Knife Perfexion unit in the management of patients with 10 or more brain metastases.
    Grandhi R; Kondziolka D; Panczykowski D; Monaco EA; Kano H; Niranjan A; Flickinger JC; Lunsford LD
    J Neurosurg; 2012 Aug; 117(2):237-45. PubMed ID: 22631694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.